Cecile Bonnafous

Marseille, France

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 17 publications

A tetraspecific engager armed with a non-alpha IL-2 variant harnesses natural killer cells against B cell non-Hodgkin lymphoma.

A tetraspecific engager armed with a non-alpha IL-2 variant harnesses natural killer cells against B cell non-Hodgkin lymphoma.

Journal: Science immunology
Published: November 15, 2024

KIR3DL2 may represent a novel therapeutic target in aggressive systemic peripheral T-cell lymphoma.

KIR3DL2 may represent a novel therapeutic target in aggressive systemic peripheral T-cell lymphoma.

Journal: Haematologica
Published: October 04, 2022

KIR3DL2 contributes to the typing of acute adult T-cell leukemia and is a potential therapeutic target.

KIR3DL2 contributes to the typing of acute adult T-cell leukemia and is a potential therapeutic target.

Journal: Blood
Published: April 21, 2022

Autologous T cell responses to primary human colorectal cancer spheroids are enhanced by ectonucleotidase inhibition.

Autologous T cell responses to primary human colorectal cancer spheroids are enhanced by ectonucleotidase inhibition.

Journal: Gut
Published: November 12, 2021

Targeting MICA/B with cytotoxic therapeutic antibodies leads to tumor control.

Targeting MICA/B with cytotoxic therapeutic antibodies leads to tumor control.

Journal: Open research Europe
Published: October 18, 2021

Antitumor immunity induced by antibody-based natural killer cell engager therapeutics armed with not-alpha IL-2 variant.

Antitumor immunity induced by antibody-based natural killer cell engager therapeutics armed with not-alpha IL-2 variant.

Journal: Cell reports. Medicine
Published: October 04, 2021

IPH4102, a first-in-class anti-KIR3DL2 monoclonal antibody, in patients with relapsed or refractory cutaneous T-cell lymphoma: an international, first-in-human, open-label, phase 1 trial.

IPH4102, a first-in-class anti-KIR3DL2 monoclonal antibody, in patients with relapsed or refractory cutaneous T-cell lymphoma: an international, first-in-human, open-label, phase 1 trial.

Journal: The Lancet. Oncology
Published: March 08, 2019

NKp46 is a diagnostic biomarker and may be a therapeutic target in gastrointestinal T-cell lymphoproliferative diseases: a CELAC study.

NKp46 is a diagnostic biomarker and may be a therapeutic target in gastrointestinal T-cell lymphoproliferative diseases: a CELAC study.

Journal: Gut
Published: August 10, 2018

Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells.

Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells.

Journal: Cell
Published: June 13, 2018

KIR3DL2 expression in patients with adult T-cell lymphoma/leukaemia.

KIR3DL2 expression in patients with adult T-cell lymphoma/leukaemia.

Journal: The British journal of dermatology
Published: January 10, 2018

KIR3DL2 expression in cutaneous T-cell lymphomas: expanding the spectrum for KIR3DL2 targeting.

KIR3DL2 expression in cutaneous T-cell lymphomas: expanding the spectrum for KIR3DL2 targeting.

Journal: Blood
Published: November 02, 2017

KIR3DL2 (CD158k) is a potential therapeutic target in primary cutaneous anaplastic large-cell lymphoma.

KIR3DL2 (CD158k) is a potential therapeutic target in primary cutaneous anaplastic large-cell lymphoma.

Journal: The British journal of dermatology
Published: February 23, 2016
Showing 1-12 of 17

Last Updated: 09/26/2026